Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

Por Muñoz, Delicias, Escartín, Antonio, Dapena, Dolores, Coret, Francisco, Fernández-Uría, Dionisio, Pérez, Domingo, Casanova, Bonaventura, Guijarro-Castro, Cristina, Munteis, Elvira, del-Campo Amigo, María, Pego, Robustiano, Calles, Carmen, García-Rey, César, Monsalve, Nuria, Sánchez-Matienzo, David
Publicado em 2013